A Multi-Center Study of BRCA1 and BRCA2 Germline Mutations in Mexican-Mestizo Breast Cancer Families Reveals Mutations Unreported in Latin American Population

The presence of germline and somatic deleterious mutations in the and genes has important clinical consequences for breast cancer (BC) patients. Analysis of the mutational status in genes is not yet common in public Latin American institutions; thus, our objective was to implement high-performance t...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2019-08, Vol.11 (9), p.1246
Main Authors: Millan Catalan, Oliver, Campos-Parra, Alma D, Vázquez-Romo, Rafael, Cantú de León, David, Jacobo-Herrera, Nadia, Morales-González, Fermín, López-Camarillo, César, Rodríguez-Dorantes, Mauricio, López-Urrutia, Eduardo, Pérez-Plasencia, Carlos
Format: Article
Language:English
Subjects:
BRCA1 protein
BRCA2 protein
Breast cancer
Developing countries
Hispanic Americans
LDCs
Mutation
Next-generation sequencing
Ovarian cancer
Patients
Population
Reagents
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The presence of germline and somatic deleterious mutations in the and genes has important clinical consequences for breast cancer (BC) patients. Analysis of the mutational status in genes is not yet common in public Latin American institutions; thus, our objective was to implement high-performance technology with highly reliable results with the possibility of analyzing several patients simultaneously, therefore reducing cost and work time. A prospective cohort of 252 unrelated sporadic breast cancer patients from the Mexican-mestizo population were analyzed using next generation sequencing (NGS) based on ion semiconductor sequencing. We found 28 pathogenic mutations (25 in and 13 in ), 11 of which had not been reported previously in Hispanic or Latin American populations. A total of 38 patients were positive for a pathogenic mutation representing 15% of our Mexican women cohort with breast cancer; 25 for ; and 13 for . Our results revealed that there are mutations not analyzed by mutations panels, and our findings support the suitability of massive sequencing approaches in the public institutions of developing countries. Hence, screening should be offered to patients with breast cancer regardless of their family history of cancer in order to identify unaffected family carriers.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers11091246